ClinicalTrials.gg
CompletedNCT03357263Updated Nov 19, 2018

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

A Phase 1 interventional study of GC3114 and GCFLU Quadrivalent in Influenza, Human, sponsored by Green Cross Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Green Cross Corporation · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Influenza, Human by GC Biopharma Corp. — 1 open to participants now, 1 under way, 1 of them phase 3. Influenza, Human · GC Biopharma Corp..

Enrollment
16th of 16
40 · median 407
Started
2017
with 1 other
Phase 1
Only one
of the 16
Registered
14th of 16
by date

Among the 16 studies in Influenza, Human by GC Biopharma Corp., this one is the 16th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 1, and was the 14th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 16 studies in Influenza, Human by GC Biopharma Corp. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Influenza, Human by GC Biopharma Corp., or all of them as a file.
02

Study summary

Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..

Read the detailed description

Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj.. Safety and immunological efficacy will be evaluated.

03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19-64 years old
  • form has been signed and dated
  • Able to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Known systemic hypersensitive to eggs, chicken proteins, or any of the vaccine components
  • Personal history of Guillain-Barre syndrome(GBS)
  • Subjects with severe chronic disease who are considered by investigator to be ineligible for the study
  • Subjects who received a vaccination within 28 days before enrollment or who are scheduled for another vaccination during the study
  • subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy
  • Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    GC3114

    Pre-filled syringe inj., 0.5ml, Once, IM

    Biological: GC3114

  • Active comparator
    GCFLU Quadrivalent

    Pre-filled syringe inj., 0.5ml, Once, IM

    Biological: GCFLU Quadrivalent

Interventions

  • BiologicalGC3114

    High-dose Quadrivalent influenza vaccine

  • BiologicalGCFLU Quadrivalent

    Quadrivalent influenza vaccine

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Solicited/Unsolicited Adverse Event

    Time frame: for 7 days from Day0/during study period

Secondary outcomes

  1. Percentage of participants achieving pre-defined Seroconversion Before and following vaccination

    Seroconversion rate (SCR)

    Time frame: Day 0 and Day 21

  2. Percentage of participants achieving pre-defined Seroprotection Before and following vaccination

    Seroprotection rate (SPR)

    Time frame: Day 0 and Day 21

  3. Geometric Mean Titer and Geometric Mean Titer Ratios of Antibodies to the Investigational Product Before and Following vaccination

    Geometric Mean Titer(GMT), Geometric Mean Titer(GMT)

    Time frame: Day 0 and Day 21

07

Study locations

1 site
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Noh JY, Jang YS, Lee SN, Choi MJ, Yoon JG, Yu DH, Song JY, Cheong HJ, Kim WJ. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Vaccine. 2019 Aug 23;37(36):5171-5176. doi: 10.1016/j.vaccine.2019.07.076. Epub 2019 Jul 31. PubMed 31377075 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2017, 1 month.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2017
First posted
Nov 29, 2017
StartActual
Nov 20, 2017
Primary completionActual
Dec 22, 2017
CompletionActual
Dec 22, 2017
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03357263
Responsible party
Sponsor
First posted
Nov 29, 2017
Start date
Nov 20, 2017
Primary completion
Dec 22, 2017
Completion
Dec 22, 2017
Last update
Nov 19, 2018

Study contacts

Woo Joo KIm, M.D, Ph.D
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion